The availability of Drizalma sprinkle expands company's portfolio of alternative formulation products designed for individuals with swallowing difficulties, the company said.
Sun Pharma has invested around $1 billion in the specialty business in US.
Net Sales are expected to increase by 15.2 percent Y-o-Y (down 4.6 percent Q-o-Q) to Rs. 7,988.9 crore, according to Emkay.
The product offers the highest concentration of cyclosporine for ophthalmic use approved by the United States Food and Drug Administration (USFDA), it added.
We have collated a list of stocks that remained in focus on August 29 because of their price action. The technical outlook is limited to near and medium-term.
Cautious and tepid commentaries by several corporates raise concern for the further earnings downgrades thus, Q2FY20 is expected to be muted as well
The total addressable market size for all these eight products is about $1 billion (as per recent IQVIA data) in Mainland China.
HDFC Securities is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 545 in its research report dated August 14, 2019.
Aalok, who is currently the Senior-Vice President, Emerging Markets and Global R&D, will have additional responsibility for generic business development.
The healthcare major's June quarter earnings beat analyst expectations on all parameters, with profit growing more than 31 percent on growth in India and US businesses.
Net Sales are expected to increase by 8 percent Y-o-Y (up 9.4 percent Q-o-Q) to Rs. 7,709.3 crore, according to Prabhudas Lilladher.
The interim analysis revealed that over 71 percent of patients treated with Ilumya experienced a 20 percent improvement in joint and skin symptoms, meeting the primary endpoint of the study, Sun Pharma said in a statement.
The global financial firm attributed the downgrade to Sun Pharma's spending in speciality pharma which will impact the company's profit growth.
HDFC Securities is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 600 in its research report dated May 29, 2019.
The pharma major in a filing on May 28 said Valia will step down from the position of the company's whole-time director to non-executive, non-independent director from May 29, 2019.
On May 16, S&P BSE Oil & Gas rose 1.5 percent, followed by the S&P BSE realty that gained 1.3 percent, and the S&P BSE Power that was up 1.3 percent
The companies have been accused of violating antitrust laws by fixing prices and allocating customers.
Sun Pharma has support around 370-390 but it seems unlikely that the stock will hold on to that level.
On Sudhir Valia, Shanghvi said he continues to be a valuable resource for the company, but over the last couple of years, he has decided to focus more on pursuits outside Sun Pharma.
The health regulator had inspected the company's Dadra facility from March 22 - March 29, 2019; and at the conclusion of the inspection, had issued a Form 483, with 11 observations to the company.
Net Sales are expected to increase by 8.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs. 7,252.9 crore, according to Prabhudas Lilladher.
Sun Pharma has fulfilled its commitments by undoing two transactions that had discomfited investors. If there’s one thing it could have done better, it is making fuller disclosures
The Baska injectibles plant had recently filed for approvals to sell its products in the US, which is currently Sun Pharma's biggest market.